Bone-formation brake
Osteocytic sclerostin release↓
Also searched as Osteocytic sclerostin release.
An approved sclerostin-blocking medicine is quoted on the Wnt-to-bone link; this is its target.
In depth
The brake on bone formation, released by osteocytes under low load. A knockout paradox the evidence shows: removing it is necessary but not sufficient for the osteogenic response, and the effect is spatially uneven.
What drives it
Training load reduces it.
10.3389/fendo.2022.954895 — Mechanical loading suppresses sclerostin - the PIEZO1 osteocyte load-sensing mechanism named in the bone set. doi 10.3389/fendo.2022.954895
What it drives
It reduces Tissue renewal signaling.
10.1159/000355781 — Sclerostin is the osteocyte-derived inhibitor of Wnt signaling in bone. ROMOSOZUMAB, an FDA-approved sclerostin inhibitor, is already quoted on the Wnt → Bone Density link. doi 10.1159/000355781
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.